Skin rash linked to better outcomes for patients with lung cancerDecember 20th, 2010 - 5:30 pm ICT by ANI
London, Dec 20 (ANI): A study has indicated that development of a skin rash after treatment with cetuximab is associated with better outcomes for patients with non-small-cell lung cancer (NSCLC).
Patients who developed an acne-like rash within the first three weeks of treatment with chemotherapy plus cetuximab lived significantly longer, experienced better progression free survival (PFS), and had a higher response rate.
These findings have suggested that an early skin rash could be a means of identifying patients most likely to respond to cetuximab treatment and who would gain the greatest survival benefit.
In this study, Ulrich Gatzemeier from Hospital Grosshansdorf in Germany and colleagues did a subgroup analysis of patients from the First-Line Erbitux in Lung Cancer (FLEX) study to assess whether the development of an acne-like rash in the first 3 weeks of treatment (first-cycle rash) correlated with clinical outcome.
The findings have shown that the presence of a rash was associated with better overall survival and a higher response rate.
The significant overall survival benefit was noted in all NSCLC histological subgroups assessed including adenocarcinoma and squamous-cell carcinoma.
“The results of our study suggest the existence of a mechanism linking the anticancer activity of cetuximab in patients with advanced NSCLC and the early incidence of acne-like rash…an alternative explanation is that cetuximab induces rash in an unrecognised subpopulation of patients with good prognosis,” said the authors.
The study was published in The Lancet Oncology. (ANI)
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
- Cetuximab drug with chemo may cut death risk in lung cancer patients - Sep 22, 2009
- Blood test could identify lung cancer patients likely to respond to drug erlotinib - May 01, 2010
- TTF therapy, chemo combo 'increase survival for lung cancer patients' - Oct 11, 2010
- Acne is more than a nuisance for some adolescents - Mar 16, 2011
- Lung cancer culprit could offer therapeutic target - Sep 14, 2010
- New treatment strategy effective for certain lung cancers - Mar 11, 2011
- Combining radiation therapy, chemo safely treats head and neck cancers - Nov 04, 2010
- New discovery shows promise against non-small cell lung cancer - Dec 04, 2010
- Lung cancer patients' pre-treatment life quality can predict odds of survival - Sep 03, 2009
- People With Severe Acne Have Increased Suicide Risk - Nov 13, 2010
- New drug shows dramatic results in reducing lung cancer tumours - Jun 23, 2010
- Soy 'ups radiation's ability to destroy lung cancer cells' - Apr 02, 2011
- Colored light sources paving way for new office, home-based skin devices - Mar 16, 2011
- Obesity, knee osteoarthritis cut down healthy years of life - Feb 16, 2011
Tags: adenocarcinoma, anticancer activity, carcinoma, cell lung cancer, cetuximab, clinical outcome, erbitux, free survival, lancet oncology, lung cancer, non small cell lung cancer, pfs, prognosis, response rate, skin rash, small cell lung cancer, squamous cell carcinoma, subgroup analysis, subgroups, survival benefit